Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 13 of 27
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
NCT02708095
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
NCT02688088
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
NCT02659020
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
NCT02714569
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
NCT02555644
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
NCT02572687
A Study of Abemaciclib in Healthy Participants
NCT02677844
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
NCT02576938
A Study of Abemaciclib in Healthy Participants
NCT02672423
A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes
NCT02588950
A Study of LY3039478 in Healthy Participants
NCT02659865
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
NCT02624778
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
NCT02564198
A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)
NCT02614716
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
NCT02589665
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
NCT02614196
A Study of Mirikizumab (LY3074828) in Healthy Participants
NCT02568423
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
NCT02614131
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
NCT02614183
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
NCT02614261
A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
NCT02614287
A Study of LY3113593 in Participants With Chronic Kidney Disease
NCT02604160
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
NCT02597036
A Study of LY3200327 in Healthy Participants
NCT02595736
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
NCT02597049
A Study of LY3154207 on Sleep in Healthy Male Participants
NCT02603861
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
NCT02561078
A Study of Galcanezumab in Healthy Participants
NCT02576951
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
NCT02514551
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392507
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
NCT02565186
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
NCT02518113
A Study of [¹⁴C]-LY3023414 in Healthy Participants
NCT02575703
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
NCT02562768
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
NCT02584855
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT02451943
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
NCT02451930
A Study of [¹⁴C]-LY3202626 in Healthy Male Participants
NCT02555449
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
NCT02543918
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
NCT02529553
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
NCT02450539
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
NCT02513550
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT02441946
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
NCT02443324
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
NCT02435433
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
NCT02426125
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
NCT02443883
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
NCT02443337
A Study of Galcanezumab in Participants With Chronic Cluster Headache
NCT02438826
A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
NCT02482935
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.